405 related articles for article (PubMed ID: 22158035)
1. Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells.
Khanal P; Yun HJ; Lim SC; Ahn SG; Yoon HE; Kang KW; Hong R; Choi HS
Oncogene; 2012 Aug; 31(34):3845-56. PubMed ID: 22158035
[TBL] [Abstract][Full Text] [Related]
2. Prolyl isomerase PIN1 negatively regulates SGK1 stability to mediate tamoxifen resistance in breast cancer cells.
Jo A; Yun HJ; Kim JY; Lim SC; Choi HJ; Kang BS; Choi BY; Choi HS
Anticancer Res; 2015 Feb; 35(2):785-94. PubMed ID: 25667458
[TBL] [Abstract][Full Text] [Related]
3. The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer.
Namgoong GM; Khanal P; Cho HG; Lim SC; Oh YK; Kang BS; Shim JH; Yoo JC; Choi HS
J Biol Chem; 2010 Jul; 285(31):23829-41. PubMed ID: 20479004
[TBL] [Abstract][Full Text] [Related]
4. PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pin1 induction in tamoxifen-resistant breast cancer cells.
Lee KY; Lee JW; Nam HJ; Shim JH; Song Y; Kang KW
Mol Cells; 2011 Jul; 32(1):107-11. PubMed ID: 21573702
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of vascular endothelial growth factor-mediated angiogenesis in tamoxifen-resistant breast cancer cells: role of Pin1 overexpression.
Kim MR; Choi HS; Yang JW; Park BC; Kim JA; Kang KW
Mol Cancer Ther; 2009 Aug; 8(8):2163-71. PubMed ID: 19671742
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells.
Kim MR; Choi HK; Cho KB; Kim HS; Kang KW
Cancer Sci; 2009 Oct; 100(10):1834-41. PubMed ID: 19681904
[TBL] [Abstract][Full Text] [Related]
7. The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation.
Lee NY; Choi HK; Shim JH; Kang KW; Dong Z; Choi HS
Carcinogenesis; 2009 Apr; 30(4):671-81. PubMed ID: 19168580
[TBL] [Abstract][Full Text] [Related]
8. COT phosphorylates prolyl-isomerase Pin1 to promote tumorigenesis in breast cancer.
Kim G; Khanal P; Kim JY; Yun HJ; Lim SC; Shim JH; Choi HS
Mol Carcinog; 2015 Jun; 54(6):440-8. PubMed ID: 24265246
[TBL] [Abstract][Full Text] [Related]
9. Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1.
Rajbhandari P; Finn G; Solodin NM; Singarapu KK; Sahu SC; Markley JL; Kadunc KJ; Ellison-Zelski SJ; Kariagina A; Haslam SZ; Lu KP; Alarid ET
Mol Cell Biol; 2012 Jan; 32(2):445-57. PubMed ID: 22064478
[TBL] [Abstract][Full Text] [Related]
10. Prolyl-isomerase Pin1 impairs trastuzumab sensitivity by up-regulating fatty acid synthase expression.
Yun HJ; Kim JY; Kim G; Choi HS
Anticancer Res; 2014 Mar; 34(3):1409-16. PubMed ID: 24596388
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the complexity of endocrine resistance in breast cancer by functional genomics.
Swanton C; Downward J
Cancer Cell; 2008 Feb; 13(2):83-5. PubMed ID: 18242507
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of angiogenesis by quercetin in tamoxifen-resistant breast cancer cells.
Oh SJ; Kim O; Lee JS; Kim JA; Kim MR; Choi HS; Shim JH; Kang KW; Kim YC
Food Chem Toxicol; 2010 Nov; 48(11):3227-34. PubMed ID: 20804812
[TBL] [Abstract][Full Text] [Related]
13. Amurensin G inhibits angiogenesis and tumor growth of tamoxifen-resistant breast cancer via Pin1 inhibition.
Kim JA; Kim MR; Kim O; Phuong NT; Yun J; Oh WK; Bae K; Kang KW
Food Chem Toxicol; 2012 Oct; 50(10):3625-34. PubMed ID: 22842120
[TBL] [Abstract][Full Text] [Related]
14. Prolyl isomerase Pin1 negatively regulates the stability of SUV39H1 to promote tumorigenesis in breast cancer.
Khanal P; Kim G; Lim SC; Yun HJ; Lee KY; Choi HK; Choi HS
FASEB J; 2013 Nov; 27(11):4606-18. PubMed ID: 23934277
[TBL] [Abstract][Full Text] [Related]
15. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
16. p53 Retards cell-growth and suppresses etoposide-induced apoptosis in Pin1-deficient mouse embryonic fibroblasts.
Shimazaki K; Uchida T; Komine A; Takahashi K
Biochem Biophys Res Commun; 2012 May; 422(1):133-8. PubMed ID: 22564744
[TBL] [Abstract][Full Text] [Related]
17. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
19. The prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor α in breast cancer.
Lucchetti C; Caligiuri I; Toffoli G; Giordano A; Rizzolio F
PLoS One; 2013; 8(2):e55355. PubMed ID: 23390529
[TBL] [Abstract][Full Text] [Related]
20. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
Iorns E; Turner NC; Elliott R; Syed N; Garrone O; Gasco M; Tutt AN; Crook T; Lord CJ; Ashworth A
Cancer Cell; 2008 Feb; 13(2):91-104. PubMed ID: 18242510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
